Data temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.

Investlytic score: 2/5 criteria met. Data as of 17/09/2026.
- ❌ Price trend failed
- ⚠️ Mixed growth
- ❌ Debt failed
- ✅ P/E passed
- ✅ Correction passed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2018 → 2019: 72.89%
Price change 2019 → 2020: -35.17%
Price change 2020 → 2021: -2.88%
Price change 2021 → 2022: -10.16%
Price change 2022 → 2023: 6.06%
Price change 2023 → 2024: -55.41%
Price change 2024 → 2025: 6.41%
Price change 2025 → 2026: 3.94%
Price change 2026 (year to date): 8.21%
Financial growth
Revenue CAGR (8 years): 1.99%
Earnings CAGR (8 years): -12.71%
Growth status: positive trend (>1%/yr) in revenue OR earnings, but not both.
Debt
Debt-to-equity ratio: 5.65
Debt/equity > 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: 24.82
P/E < 25.0 (maximum threshold).
Correction (6 months)
Current correction: 14.32% from the high over 6 months.
Correction between 10.0% and 20.0% (target range).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="NRC" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| National Research Corporation | 31.5 | 5.65 | +5.3 % | 🔒 |
| Lumibird S.A. | 38.1 | 0.71 | +9.8 % | – |
| Valneva SE | – | 1.95 | +22.4 % | – |
| 4D Molecular Therapeutics, Inc. | – | 0.04 | +40.0 % | – |
| Equasens S.A. | 10.6 | 0.21 | +6.5 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Key reported figures
Revenue, net income and net margin reported by NRC Health over the latest fiscal years.
| Fiscal year | Revenue | Net income | Net margin | Revenue growth |
|---|---|---|---|---|
| 2020 | 133 m | 37.3 m | 28.0 % | n/a |
| 2021 | 148 m | 37.5 m | 25.3 % | +11.0 % |
| 2022 | 152 m | 31.8 m | 21.0 % | +2.4 % |
| 2023 | 149 m | 31.0 m | 20.8 % | -2.0 % |
| 2024 | 143 m | 24.8 m | 17.3 % | -3.7 % |
| 2025 | 137 m | 11.6 m | 8.4 % | -4.0 % |
Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.
Accounts and financial health
Balance sheet and cash flow published by NRC Health over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash and investments | 54.4 m | 25.0 m | 6.7 m | 4.2 m | 4.1 m |
| Total Debt | 28.7 m | 23.4 m | 39.0 m | 64.4 m | 79.0 m |
| Net Debt | -25.7 m | -1.6 m | 32.3 m | 60.2 m | 74.9 m |
| Equity | 85.3 m | 72.0 m | 49.0 m | 31.3 m | 14.0 m |
| Total assets | 158 m | 130 m | 122 m | 133 m | 135 m |
| Operating cash flow | 46.3 m | 36.3 m | 38.1 m | 34.6 m | 26.4 m |
| Investments (capex) | 5.5 m | 9.8 m | 15.8 m | 15.4 m | 10.7 m |
| Free cash-flow | 40.8 m | 26.4 m | 22.3 m | 19.2 m | 15.7 m |
| Share buybacks | 4.1 m | 27.6 m | 19.1 m | 30.9 m | 20.2 m |
| Dividends paid | 9.2 m | 21.0 m | 36.4 m | 11.5 m | 11.0 m |
Amounts in USD, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 16/11/2026.
Valuation and competitors
NRC Health compared with its sector on the same exchange and with its main competitors.
Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about NRC Health
What is the NRC Health share price?
Latest recorded price: 26.56 USD on 13/11/2026, for a market cap of 564 m USD.
What is the revenue of NRC Health?
137 m USD for fiscal year 2025, with net income of 11.6 m USD (net margin 8.4 %).
What is the P/E ratio of NRC Health?
Trailing 12-month P/E of 32.4, against 20.8 for the sector median on the same exchange (10-year median: 28.2).
Is NRC Health stock eligible for the French PEA?
No: the company is headquartered outside the European Union and the European Economic Area (ISIN US6373722023).
How many employees does NRC Health have?
368 full-time employees according to the latest published profile.
Who runs NRC Health?
Michael D. Hays is the company's chief executive.